Comparison of Diskus inhaler, a new multidose powder inhaler, with Diskhaler inhaler for the delivery of salmeterol to asthmatic patients. Canadian Study Group.
Administration of the long-acting beta 2-adrenoceptor agonist salmeterol from a new, easy-to-operate, multidose powder inhaler (Diskus) containing 60 sealed doses in a foil strip has been compared with administration from a Diskhaler inhaler in a multicenter, double-blind, double-dummy, parallel-group study. Asthmatic patients taking anti-inflammatory treatment, with baseline FEV1 > or = 60% and < or = 90% predicted were treated for 4 weeks with salmeterol 50 micrograms twice daily from either the Diskus or Diskhaler inhaler. The two treatments were equivalent (90% CLs for the difference in mean morning PEFR: -2.2, 8.7 L/min). The Diskus inhaler was rated easier to use and was preferred by more patients than the Diskhaler inhaler (73% vs. 15%).
Boulet
L P
LP
Hôpital Laval, Sainte-Foy, Quebec, Canada.
Cowie
R
R
Johnston
P
P
Krakovsky
D
D
Mark
S
S
D000293:Adolescent; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage* / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000420:Albuterol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D002648:Child; D004311:Double-Blind Method; D004867:Equipment Design; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009330:Nebulizers and Vaporizers; D017060:Patient Satisfaction; D010366:Peak Expiratory Flow Rate; D011208:Powders; D000068299:Salmeterol Xinafoate
D000318:Adrenergic beta-Agonists; D011208:Powders; D000068299:Salmeterol Xinafoate; D000420:Albuterol